XOMA Corporation logo
XOMA Corporation XOMA

Annual report 2025
added 03-18-2026

report update icon

XOMA Corporation Balance Sheet 2011-2026 | XOMA

Annual Balance Sheet XOMA Corporation

2025 2024 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

16 M 5.67 M -95.1 M -58.7 M -24.4 M -23.3 M -28.9 M 17.4 M -17.1 M -42.9 M -60.7 M -4.3 M -14.8 M

Long Term Debt

96.5 M 107 M 119 M - 34 K 12.8 M 27.1 M 21.7 M 14.6 M 25.3 M 42.8 M 16.3 M 35.2 M 37.7 M 33.5 M

Long Term Debt Current

2.46 M 446 K 54 K 34 K 195 K 179 K 163 K 789 K - 17.9 M 5.91 M 19.2 M 5.84 M 3.39 M 2.8 M

Total Non Current Liabilities

- - - - - 26.6 M 42.9 M 39.3 M 31.7 M 43.4 M 53.9 M 50.1 M 109 M 60.4 M 42 M

Total Current Liabilities

34.8 M 24.4 M 19.5 M 6.82 M 13 M 12.3 M 8.88 M 5.7 M 7.42 M 32.5 M 23.3 M 36.5 M 29.6 M 23.7 M 21 M

Total Liabilities

169 M 139 M 146 M 16.4 M 24.7 M 38.9 M 51.7 M 45 M 39.1 M 75.9 M 77.2 M 86.5 M 139 M 84.2 M 63 M

Deferred Revenue

- - - - - 1.45 M 1.89 M 1.29 M 1.41 M 899 K 3.2 M 1.09 M 2.22 M 3.41 M 5.7 M

Retained Earnings

-1.22 B -1.24 B -1.22 B -1.18 B -1.17 B -1.18 B -1.19 B -1.19 B -1.18 B -1.19 B -1.14 B -1.12 B -1.08 B -957 M -886 M

Total Assets

273 M 221 M 234 M 140 M 167 M 125 M 95.7 M 63.8 M 44.9 M 28.7 M 74.9 M 89.6 M 135 M 106 M 78 M

Cash and Cash Equivalents

82.9 M 102 M 153 M 57.8 M 93.3 M 84.2 M 56.7 M 45.8 M 43.5 M 25.7 M 65.8 M 78.4 M 102 M 45.3 M 48.3 M

Book Value

104 M 81.9 M 88.7 M 124 M 142 M 86.4 M 44 M 18.8 M 5.79 M -47.2 M -2.31 M 3.1 M -3.99 M 21.5 M 15 M

Total Shareholders Equity

83.9 M 61.9 M 88.7 M 124 M 142 M 86.4 M 44 M 18.8 M 5.79 M -47.2 M -2.31 M 3.1 M -3.99 M 21.5 M 15 M

All numbers in USD currency

Quarterly Balance Sheet XOMA Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

94.4 M 102 M 99.9 M 107 M 108 M 115 M - 119 M - - - - - - - 34 K 85 K 133 K 11.7 M 12.8 M 12.8 M 12.8 M 12.8 M 27.1 M 27.1 M 27.1 M 27.1 M 21.7 M 21.7 M 21.7 M 21.7 M 14.6 M 14.6 M 14.6 M 14.6 M 25.3 M 25.3 M 25.3 M 25.3 M 42.8 M 42.8 M 42.8 M 42.8 M 16.3 M 16.3 M 16.3 M 16.3 M 35.2 M 35.2 M 35.2 M 35.2 M 37.7 M 37.7 M 37.7 M 37.7 M 33.5 M 33.5 M 33.5 M 33.5 M

Total Liabilities

155 M 131 M 128 M 139 M 139 M 143 M - 146 M 18.1 M 15.5 M 19.1 M 16.4 M 15.8 M - 19.2 M 24.7 M 18.9 M 19.2 M 38.2 M 38.9 M 38.9 M 38.9 M 38.9 M 51.7 M 51.7 M 51.7 M 51.7 M 45 M 45 M 45 M 45 M 39.1 M 39.1 M 39.1 M 39.1 M 75.9 M 75.9 M 75.9 M 75.9 M 77.2 M 77.2 M 77.2 M 77.2 M 86.3 M 86.3 M 86.3 M 86.3 M 139 M 139 M 139 M 139 M 84.2 M 84.2 M 84.2 M 84.2 M 63 M 63 M 63 M 63 M

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - 798 K 798 K 798 K 798 K 798 K 851 K 595 K 490 K 1.12 M 171 K 490 K 615 K 615 K 615 K 615 K 899 K 899 K 899 K 899 K 3.2 M 3.2 M 3.2 M 3.2 M 1.09 M 1.09 M 1.09 M 1.09 M 2.22 M 2.22 M 2.22 M 2.22 M 3.41 M 3.41 M 3.41 M 3.41 M 5.7 M 5.7 M 5.7 M 5.7 M

Retained Earnings

-1.21 B -1.23 B -1.24 B -1.24 B -1.23 B -1.22 B - -1.22 B -1.2 B -1.2 B -1.19 B -1.18 B -1.18 B - -1.17 B -1.17 B -1.2 B -1.19 B -1.19 B -1.18 B -1.18 B -1.18 B -1.18 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.19 B -1.18 B -1.18 B -1.18 B -1.18 B -1.19 B -1.19 B -1.19 B -1.19 B -1.14 B -1.14 B -1.14 B -1.14 B -1.12 B -1.12 B -1.12 B -1.12 B -1.08 B -1.08 B -1.08 B -1.08 B -957 M -957 M -957 M -957 M -886 M -886 M -886 M -886 M

Total Assets

263 M 223 M 213 M 221 M 223 M 243 M - 234 M 124 M 126 M 134 M 140 M 146 M - 159 M 167 M 131 M 136 M 120 M 125 M 125 M 125 M 125 M 95.7 M 95.7 M 95.7 M 95.7 M 63.8 M 63.8 M 63.8 M 63.8 M 44.9 M 44.9 M 44.9 M 44.9 M 28.7 M 28.7 M 28.7 M 28.7 M 74.9 M 74.9 M 74.9 M 74.9 M 89.4 M 89.4 M 89.4 M 89.4 M 135 M 135 M 135 M 135 M 106 M 106 M 106 M 106 M 78 M 78 M 78 M 78 M

Cash and Cash Equivalents

45.2 M 75.1 M 90.3 M 102 M 147 M 150 M 142 M 153 M 33.5 M 31.4 M 44.3 M 57.8 M 78.3 M 83.2 M 88.6 M 93.3 M 72.2 M 78.9 M 67.8 M 84.2 M 84.2 M 84.2 M 84.2 M 56.7 M 56.7 M 56.7 M 56.7 M 45.8 M 28.4 M 38.7 M 42 M 43.5 M 43.5 M 43.5 M 43.5 M 25.7 M 25.7 M 25.7 M 25.7 M 65.8 M 65.8 M 65.8 M 65.8 M 78.4 M 78.4 M 78.4 M 78.4 M 102 M 102 M 102 M 102 M 45.3 M 45.3 M 45.3 M 45.3 M 48.3 M 48.3 M 48.3 M 48.3 M

Book Value

108 M 92.5 M 84.6 M 81.9 M 84.8 M 100 M - 88.7 M 106 M 110 M 115 M 124 M 130 M - 140 M 142 M 112 M 117 M 81.7 M 86.4 M 86.4 M 86.4 M 86.4 M 44 M 44 M 44 M 44 M 18.8 M 18.8 M 18.8 M 18.8 M 5.79 M 5.79 M 5.79 M 5.79 M -47.2 M -47.2 M -47.2 M -47.2 M -2.31 M -2.31 M -2.31 M -2.31 M 3.1 M 3.1 M 3.1 M 3.1 M -3.99 M -3.99 M -3.99 M -3.99 M 21.5 M 21.5 M 21.5 M 21.5 M 15 M 15 M 15 M 15 M

Total Shareholders Equity

87.9 M 72.4 M 84.6 M 61.9 M 64.8 M 80 M 82.3 M 88.7 M 106 M 110 M 115 M 124 M 130 M 135 M 140 M 142 M 112 M 117 M 81.7 M 86.4 M 86.4 M 86.4 M 86.4 M 44 M 44 M 44 M 44 M 18.8 M 18.8 M 18.8 M 18.8 M 5.79 M 5.79 M 5.79 M 5.79 M -47.2 M -47.2 M -47.2 M -47.2 M -2.31 M -2.31 M -2.31 M -2.31 M 3.1 M 3.1 M 3.1 M 3.1 M -3.99 M -3.99 M -3.99 M -3.99 M 21.5 M 21.5 M 21.5 M 21.5 M 15 M 15 M 15 M 15 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of XOMA Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 5.12 11.55 % $ 345 B britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.97 6.43 % $ 9.55 B australiaAustralia
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 320.13 -3.98 % $ 41.9 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.67 -1.27 % $ 766 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 7.66 3.23 % $ 75.7 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.81 0.6 % $ 1.02 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
BioNTech SE BioNTech SE
BNTX
- - $ 27.2 B germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
$ 3.52 3.53 % $ 354 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.08 -2.84 % $ 5.07 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.26 -11.72 % $ 144 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.35 -12.9 % $ 347 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.26 0.47 % $ 456 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.6 -1.04 % $ 6.83 B spainSpain
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.19 -1.59 % $ 3.08 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.61 8.05 % $ 428 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 33.86 -0.03 % $ 2.25 B usaUSA